NOTE: This order is nonprecedential. United States Court of Appeals
for the Federal Circuit REGENERON PHARMACEUTICALS, INC.,
Plaintiff-Appellee
v.
MYLAN PHARMACEUTICALS INC., BIOCON
BIOLOGICS INC.,
Defendants-Appellants
AMGEN USA, INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD., FORMYCON AG, AMGEN INC.,
Defendants
2024-2002
Appeal from the United States District Court for the Northern District of West Virginia in Nos. 1:22-cv-00061-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK-JPM, 1:24-cv-00053-TSK, 1:24-md-03103-TSK-JPM, Chief Judge Thomas S. Kleeh.
O R D E R
The parties, having so agreed, IT IS ORDERED THAT:
22 REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC. The above-captioned appeal is dismissed under Fed. R. App. P. 42(b) with each side to bear their own costs.
FOR THE COURT
April 16, 2025 Date
ISSUED AS A MANDATE: April 16, 2025